In bioanalysis of small molecules, the analyte concentration in the measured samples should reflect the concentration during sample collection. Precautions may be needed to prevent over- or under-estimation of the obtained result. This might require the addition of stabilizers to prevent degradation or nonspecific binding. For unstable drugs, it is essential to know how analytes can be stabilized before the start of the clinical study. Although the stabilization methods are well documented, the impact of the stabilization on the clinical workflow is not properly addressed. Already during method development, the clinical implications in terms of personnel safety, ease of use, training possibilities and staff capacity should be taken into account, and validation of the bioanalytical method should reflect collection procedures.

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Van de Merbel N, de Vries R. Aging of biological matrices and its effect on bioanalytical method performance. Bioanalysis 5(19), 2393–2407 (2013).
CASGoogle Scholar
2 Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis 1(1), 205–220 (2009).•• Excellent review article on the stability issues in bioanalysis.
CASGoogle Scholar
3 Ohnmacht CM. LC–MS bioanalysis of photosensitive and oxidatively labile compound. In: Handbook Of LC–MS Bioanalysis, Best Practices Experimental Protocols And Regulations. John Wiley and Sons, Inc, NY, USA, 491–504 (2013).
Google Scholar
4 Peters FT. Stability of analytes in biosamples- an important issue in clinical and forensic toxicology? Anal. Bioanal. Chem. 388(7), 1505–1519 (2007).
Medline CASGoogle Scholar
5 Ji AJ, Jiang Z, Livson Y, Davis JA, Chu JX, Weng N. Challenges in urine bioanalytical assays: overcoming non specific binding. Bioanalysis 2(9), 1573–1586 (2010).•• Good overview of strategies for urine sampling.
CASGoogle Scholar
6 Li W, Zhang J, Tse FL. Strategies in quantitative LC–MS/MS analysis of unstable small molecules in bioanalytical matrixes. Biomed. Chromatogr. 25(1–2), 258–277 (2011).
MedlineGoogle Scholar
7 Chen J, Hsieh Y. Stabilizing drug molecules in biological samples. Ther. Drug Monit. 27(5), 617–624 (2005).
Medline CASGoogle Scholar
8 Van der Merbel N, Savoie N, Yadav M et al. Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization team. AAPS J. 16(3), 392–399 (2014).
MedlineGoogle Scholar
9 Heinig K. What are the challenges of stability investigations and sample stabilization in regulated bioanalysis. Bioanalysis 5(15), 1811–1814 (2013).• Good editorial on stability investigations and stability aspects.
CASGoogle Scholar
10 Sennbro CJ, Knutsson M, van Amsterdam P, Timmerman P. Anticoagulant counter ion impact on bioanalytical LC–MS/MS assays: results from discussions and experiments within the European Bioanalytical Forum. Bioanalysis 3(21), 2393–2399 (2011).
CASGoogle Scholar
11 Japanese Ministry of Health, Welfare and Labour. Guideline on Bioanalytical Method Validation in Pharmaceutical Development (2013).
Google Scholar
12 Brazilian Agência de Nacional de Vigilância Sanitária. Resolution- RDC Nº 27, Requirements for the validation of bioanalytical methods (2012). http://bcn2012.europeanbioanalysisforum.eu/slides/day%203/7%20updates%20from%20the%20globe/3_tavares.pdf.
Google Scholar
13 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. (2001). www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
Google Scholar
14 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. Draft Guidance. September 2013.
Google Scholar
15 European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
Google Scholar
16 Boterman M, DOIG m, Breda M et al. Recommendations on the interpretation of the new European medicines agency guideline on bioanalytical method validation by global CRO council for bioanalysis (GCC). Bioanalysis 4(6), 651–660 (2012).
CASGoogle Scholar
17 Lowes S, Jersey J, Shoup R et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the global CRO council for bioanalysis. Bioanalysis 3(12), 1223–1332 (2011).
Google Scholar
18 van Amsterdam P, Companjen A, Brudny-Kloeppel M, Golob M, Luedtke S, Timmerman P. The European Bioanalysis forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method validation. Bioanalysis 5(6), 645–659 (2013).
CASGoogle Scholar
19 Freisleben A, Brudny-Klöppel M, Mulder H, de Vries R, de Zwart M, Timmerman P. Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis. Bioanalysis 3(12), 1333–1336 (2011).
CASGoogle Scholar
20 Viswanathan CT, Basal S, Booth B et al. Workshop/Conference Report-Quantitave bioanakytical methods validation and implementation: best practices for chromatographic and ligand binding assay. AAPS J 9, E30–E42 (2007).
Google Scholar
21 Timmerman P. Tiered approach revisited: introducing stage-approach or assay-appropriate scientific validation. Bioanalysis 6(5), 599–604 (2014).• Good commentary on the level of scientific validation needed for bioanalytical studies.
CASGoogle Scholar
22 Timmerman P, White S, Knutsson M et al. Feedback from the EBF workshop: taking tiered approach to the next level. Bioanalysis 6(19), 2593–2598 (2014).
CASGoogle Scholar
23 Hilhorst MJ, Hendriks G, Van Hout MW, Sillen H, van de Merbel NC. HPLC–MS/MS method for the determination of cytarabine in human plasma. Bioanalysis 3(14), 1603–1611 (2011).
CASGoogle Scholar
24 Fung EN, Zheng N, Arnold ME et al. Effective screening approach to select esterase inhibitors used for stabilizing ester containing prodrugs analyzed by LC–MS/MS. Bioanalysis 2(4), 733–743 (2010).• General article on the use of enzyme inhibitors.
CASGoogle Scholar
25 Du L, Musson DG. Stability studies of vorinostat and its two metabolites in human plasma serum and urine. J. Pharm. Biomed. Anal. 42(5), 556–564 (2006).
Medline CASGoogle Scholar
26 Gruenke LD, Craig JC, Klein FD et al. Determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry: application to biological fluids. Biomed. Mass Spectrom. 12(12), 707–713 (1985).
Medline CASGoogle Scholar
27 Suchocka Z, Swatowska J, Pachecka J, Suchocki P. Determination of paraoxonase 3 activity in human blood serum. J. Pharm. Biomed. Anal. 42(1), 113–119 (2006).
Medline CASGoogle Scholar
28 Bieri JG, Evarts RP, Thorpe S. Factors affecting the exchange of tocopherol between red blood cells and plasma. Am. J. Clin. Nutr. 30, 686–690 (1977).
Medline CASGoogle Scholar
29 Lentjes EG, Romijn FH. Temperature dependent cortisol distribution among blood compartments in man. J. Clin. Endocrinol. Metab. 84, 682–687 (1999).
Medline CASGoogle Scholar
30 Atkinson K, Britton K, Biggs J. Distribution and concentration of cyclosporine in human blood. J. Clin. Pathol. 37, 1167–1171 (1984).
Medline CASGoogle Scholar
31 Fišar Z, Fuksová K, Sikora J et al. Distribution of antidepressants between plasma and red blood cells. Neuroendocrinol. Lert. 27, 307–313 (2006).
Medline CASGoogle Scholar
32 Arrhenius S. Ueber die Reaktionsgeschwindigkeit bei der Inversion von Rohrzucker durch Säuren. Z. Phys. Chem. 4, 226–248 (1889).
Google Scholar
33 Arrhenius S. “Zur Theorie der chemischen Reaktionsgeschwindigkeit,” in Bihang, 24, no.2 (1898). Z. phys. Chem. 28, 317–335 (1899).
Google Scholar
34 Aranov PA, Hall LM, Dettmer K, Stephensen CB, Hammock BD. Metabolic profiling of major vitamin D metabolites using Diels Alder derivatisation and ultra-performance-liquid – chromatogrpahy tandem mass spectrometry. Anal. Bioanal. Chem. 391, 1917–1930 (2008).
MedlineGoogle Scholar
35 Anderson A, Ehrsson H. Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate. J. Pharm. Biomed. Anal. 13, 639–644 (1995).
MedlineGoogle Scholar
36 Fura A, Harper TW, Zhang H, Fung L, Shyu WC. Shift in pH of biological fluids during storage and processing: effect on bioanalysis. J. Pharm. Biomed. Anal. 32, 513–522 (2003).
Medline CASGoogle Scholar
37 Van de Merbel N, de Vries R. Age of biological matrices and its effect on bioanalytical method performance. Bioanalysis 5(19), 2393–2407 (2013).
CASGoogle Scholar
38 T. Ebner T, Heinzel G, Prox A, Beschke, Wachsmuth H. Disposition and chemical stability of telmisartan 1-o-acylglucuronide. Drug Metab. Dispos. 27(10), 1143–1149 (1999).
MedlineGoogle Scholar
39 Dell D. Labile metabolites. Chromatographia 59, S139–S148 (2004).
CASGoogle Scholar
40 Van de Merbel, Hendriks G, Imbos R, Tuunainen J, Rouru J, Nikkanen H. Quantitative determination of free and total dopamine in human plasma by LC–MS/MS: the importance of sample preparation. Bioanalysis 3(17), 1949–1961 (2011).
CASGoogle Scholar
41 Van de Merbel NC, Bronsema KJ, van Hout MW, Nilsson R, Sillen H. A validated liquid chromatograqphy-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterole in human plasma. J. Pharm. Biomed. Anal. 55(5), 1089–1095 (2011).
Medline CASGoogle Scholar
42 Wang G, Hsieh Y, Lau Y et al. Semi-automated determination of plasma stability of drug discovery compounds using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 780(2), 451–457 (2002).
Medline CASGoogle Scholar
43 Lindegardh N, Davies GR, Hien TT et al. Importance of collection tube during clinical studies of oseltamivir. Antimicrob. Agents Chemother. 51(5), 1835–1836 (2007).
Medline CASGoogle Scholar
44 Pham-huy C, Villain-Pautet G, Hua H et al. Seperation of oxazepam. Lorazepam and temazepam enantiomers by HPLC on a derivatized cyclodextrin-bonded phase: application to the determination of oxazepam in plasma. J. Biochem. Biophys. Meth 54, 287–299 (2002).
Medline CASGoogle Scholar
45 Zhao Y, Sukbunthernq J, Antonian L. Simultanious determination of Z-Su5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS. J. Pharm. Biomed. Anal. 35(3), 513–522 (2004).
Medline CASGoogle Scholar
46 Yan KX, Song H, Lo MW. Determination of MK-0767 enantiomers in human plasma by normal phase LC–MS/MS. J. Chromatogr. B 813, 95–102 (2004).
Medline CASGoogle Scholar
47 Wang CJ, pao LH, Hsiong CH, Wu CY, Whang-Peng JJ, Hu OYP. Novel inhibition of cis/trans retinoic acid interconversion in biological fluids – an accurate method for the determination of trans and 13-cis retinoic acid in biological fluids. J. Chromatogr. B. 796(2), 283–291 (2003).
Medline CASGoogle Scholar
48 Jemal M, Khan S, Teitz DS, McCafferty JA, Hawthorne DJ. LC/MS/MS determination ofomapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl- and thioether-containing metabolites in human plasma. Anal. Chem, 73, 5450–5456 (2001).
Medline CASGoogle Scholar
49 Abu-Shandi KH, Redel E. Quantification and stability evaluation of the highly specific angiotensin-converting enzyme (ACE) inhibitor Captopril in human plasma using a gas chromatography method woth N,N,N’,N’-tetramethyl-2-butenediamide derivatisation agent. Jordan J. Chem. 4, 189–194 (2009).
Google Scholar
50 Ji AJ. LC–MS bioanalysis of drugs in urine. In: Handbook of LC–MS Bioanalysis, best practices experimental protocols and regulations. John Wiley and Sons, Inc, NY, USA, 307–316 (2013).
Google Scholar
51 Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JHM, Beijnen JH. Stability experiments in human urine with E09 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. J. Pharm. Biomed. Anal. 43(1), 285–292 (2007).
Medline CASGoogle Scholar

Vol. 7, No. 3

Metrics

Downloaded 829 times

History

Published online 20 February 2015

Published in print February 2015

Information

Disclaimer

The views expressed in this paper are the ones of the European Bioanalysis Forum and do not necessarily represent the views of the individual members’ companies.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download